Biotechnology is helping us tackle challenges such as emerging diseases, the impact of ageing in healthcare, population growth, climate change, and the green transition of the economy. Precision medicines, advanced therapies, mRNA and gene editing technologies are transforming the way diseases can be diagnosed and treated, providing life-saving solutions. Biotechnology is also at the forefront of building a sustainable economy, developing better crops, providing new protein sources, and producing bio-based materials.
SeaBeLife secures €1.2m in funding
Latest NewsBiotech company, specialising in cell necrosis prevention, has announced a successful funding round, securing €1.2m in additional seed funding.
BioSpain breaking records
Latest NewsWith more than 2,100 attendents, 4,700 partnering meetings so far, BioSpain 2023 is set to break records.
Pierre Fabre Laboratories collaborate with Vernalis
Latest NewsPierre Fabre Laboratories, a leading French medical and beauty care company and Vernalis (R&D) Ltd, a fully owned subsidiary of HitGen Inc. and a specialist in drug discovery announce a long-term partnership for oncology drug discovery.
AI – tool or trouble?
BackgroundDepending on who you talk to, artificial intelligence (AI) is either a saviour or an enslaver. The concerns range from loss of jobs through to robots running society. However, in the life sciences, the use of AI and machine learning (ML) have created some excitement over their potential applications.
Building a new industry and medicine thanks to biotech
OpinionBiotechnology is helping us tackle challenges such as emerging diseases, the impact of ageing in healthcare, population growth, climate change, and the green transition of the economy. Precision medicines, advanced therapies, mRNA and gene editing technologies are transforming the way diseases can be diagnosed and treated, providing life-saving solutions. Biotechnology is also at the forefront of building a sustainable economy, developing better crops, providing new protein sources, and producing bio-based materials.
Crucible Therapeutics spins out with £5m
Latest NewsUniversity of Sheffield spinout gets £5m for gene therapies targeting ALS and FTD, advancing towards clinical trials.
Oxford Biomedica acquires ABL Europe for €15m
Latest NewsOxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.
Austrian Kern Tec raises €12m in Series A financing
Latest NewsAustrian Kern Tec GmbH has raised €12m in the biggest Series A financing ever seen for a foodtech company in Austria to scale food production from waste.
Austria as a Life Sciences Hotspot
Sponsored PublicationsAustria has gained an outstanding reputation as a research location in the field of life sciences both as a vibrant hub for science and as a cluster for research-oriented and manufacturing companies. The ABA links international companies with this ecosystem
BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Latest NewsBritish drug discovery specialist BenevolentAI Ltd has licenced its end-to-end AI platform capabilities to Merck KGaA to deliver novel drug candidates for three targets in oncology, neurology and immunology.